Association of beta-adrenergic receptor polymorphisms and mortality in carvedilol-treated chronic heart-failure patients

British Journal of Clinical Pharmacology

Volumn 71, Issue 4, 2011, Pages 556-565

  Petersen, Morten ^a,b   Andersen, Jon T ^a,b   Hjelvang, Brian R ^a,b   Broedbaek, Kasper ^a,b   Afzal, Shoaib ^a,b   Nyegaard, Mette ^c,d   Børglum, Anders D ^d   Stender, Steen ^e,f   Køber, Lars ^a,f   Torp Pedersen, Christian ^e,f   Poulsen, Henrik E ^a,b,f  

^a Rigshospitalet   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

^d AARHUS UNIVERSITY   (Denmark)

^e GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Carvedilol; Drug gene specific interaction; Functional genotype group; Heart failure; Metoprolol; Mortality

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INSULIN; METOPROLOL; NOLOMIROLE; SPIRONOLACTONE;

ARTICLE; CARDIAC PATIENT; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENOTYPE; HEART FAILURE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHARMACOGENETICS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; AGED, 80 AND OVER; CARBAZOLES; FEMALE; GENOTYPE; HEART FAILURE; HUMANS; MALE; METOPROLOL; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROPANOLAMINES; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ADRENERGIC, BETA; SURVIVAL ANALYSIS;

EID: 79952582396     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03868.x     Document Type: Article

References (35)

1. Hayden EC. Cardiovascular disease gets personal. Nature 2009; 460: 940-1.
2. The MERIT-HF Study Group. Effect of metoprolol CR XL in chronic heart failure: Metoprolol CR XL Randomised Intervention Trial in congestive heart failure (MERIT-HF). Lancet 1999; 353: 2001-7.
3. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-8.
4. Gilbert EM, Abraham WT, Olsen S, Hattler B, White M, Mealy P, Larrabee P, Bristow MR. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996; 94: 2817-25.
5. Mason DA, Moore JD, Green SA, Liggett SB. A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem 1999; 274: 12670-4.
6. Liu J, Liu ZQ, Tan ZR, Chen XP, Wang LS, Zhou G, Zhou HH. Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol. Clin Pharmacol Ther 2003; 74: 372-9.
7. Liu J, Liu ZQ, Yu BN, Xu FH, Mo W, Zhou G, Liu YZ, Li Q, Zhou HH. Beta1-adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension. Clin Pharmacol Ther 2006; 80: 23-32.
8. Terra SG, Hamilton KK, Pauly DF, Lee CR, Patterson JH, Adams KF, Schofield RS, Belgado BS, Hill JA, Aranda JM, Yarandi HN, Johnson JA. Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. Pharmacogenet Genomics 2005; 15: 227-34.
9. Green SA, Turki J, Innis M, Liggett SB. Amino-terminal polymorphisms of the human beta(2)-adrenergic receptor impart distinct agonist-promoted regulatory properties (Vol 33, Pg 9414, 1994). Biochemistry 1994; 33: 14368-14368.
10. Kaye DM, Smirk B, Williams C, Jennings G, Esler M, Holst D. Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure. Pharmacogenetics 2003; 13: 379-82.
11. Metra M, Covolo L, Pezzali N, Zaca V, Bugatti S, Lombardi C, Bettari L, Romeo A, Gelatti U, Giubbini R, Donato F, Dei Cas L. Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure. Cardiovasc Drugs Ther 2010; 24: 49-60.
12. Flesch M, Ettelbruck S, Rosenkranz S, Maack C, Cremers B, Schluter KD, Zolk O, Bohm M. Differential effects of carvedilol and metoprolol on isoprenaline-induced changes in beta-adrenoceptor density and systolic function in rat cardiac myocytes. Cardiovasc Res 2001; 49: 371-80.
13. Arora R, Ferrick KJ, Nakata T, Kaplan RC, Rozengarten M, Latif F, Ng K, Marcano V, Heller S, Fisher JD, Travin MI. I-123 MIBG imaging and heart rate variability analysis to predict the need for an implantable cardioverter defibrillator. J Nucl Cardiol 2003; 10: 121-31.
14. Hanada K, Asari K, Saito M, Kawana J, Mita M, Ogata H. Comparison of pharmacodynamics between carvedilol and metoprolol in rats with isoproterenol-induced cardiac hypertrophy: effects of carvedilol enantiomers. Eur J Pharmacol 2008; 589: 194-200.
15. Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB. Increased beta-receptor density and improved hemodynamic-response to catecholamine stimulation during long-term metoprolol therapy in heart-failure from dilated cardiomyopathy. Circulation 1989; 79: 483-90.
16. Forleo C, Resta N, Sorrentino S, Guida P, Manghisi A, De, Luca V, Romito R, Iacoviello M, De Tommasi E, Troisi F, Rizzon B, Guanti G, Rizzon P, Pitzalis MV. Association of beta-adrenergic receptor polymorphisms and progression to heart failure in patients with idiopathic dilated cardiomyopathy. Am J Med 2004; 117: 451-8.
17. White HL, de Boer RA, Maqbool A, Greenwood D, van Veldhuisen DJ, Cuthbert R, Ball SG, Hall AS, Balmforth AJ. An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur J Heart Fail 2003; 5: 463-8.
18. Heckbert SR, Hindorff LA, Edwards KL, Psaty BM, Lumley T, Siscovick DS, Tang Z, Durda JP, Kronmal RA, Tracy RP. Beta2-adrenergic receptor polymorphisms and risk of incident cardiovascular events in the elderly. Circulation 2003; 107: 2021-4.
19. Sehnert AJ, Daniels SE, Elashoff M, Wingrove JA, Burrow CR, Horne B, Muhlestein JB, Donahue M, Liggett SB, Anderson JL, Kraus WE. Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. J Am Coll Cardiol 2008; 52: 644-51.
20. Taylor MR. Pharmacogenetics of the human beta-adrenergic receptors. Pharmacogenomics J 2007; 7: 29-37.
21. Leineweber K, Buscher R, Bruck H, Brodde OE. Beta-adrenoceptor polymorphisms. Naunyn Schmiedebergs Arch Pharmacol 2004; 369: 1-22.
22. Torp-Pedersen C, Kober L, Carlsen JE, Akkan D, Bruun NE, Dacoronias D, Dickstein K, Haghfelt T, Ohlin H, McMurray JJV. A randomised trial of a pre-synaptic stimulator of DA(2)-dopaminergic and alpha(2)-adrenergic receptors on morbidity and mortality in patients with heart failure. Eur J Heart Fail 2008; 10: 89-95.
23. Kober L, Torppedersen C, Carlsen J, Viderbaek R, Egeblad H. An echocardiographic method for selecting high-risk patients shortly after acute myocardial-infarction, for inclusion in multicenter studies (as used in the Trace Study). Eur Heart J 1994; 15: 1616-20.
24. Pedersen CB, Gotzsche H, Moller JO, Mortensen PB. The Danish civil registration system - a cohort of eight million persons. Dan Med Bull 2006; 53: 441-9.
25. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol European trial (COMET): randomised controlled trial. Lancet 2003; 362: 7-13.
26. Evans BA, Sato M, Sarwar M, Hutchinson DS, Summers RJ. Ligand-directed signalling at beta-adrenoceptors. Br J Pharmacol 2010; 159: 1022-38.
27. Bruck H, Leineweber K, Ternme T, Weber M, Heusch G, Philipp T, Brodde OE. The Arg389GIy beta(1)-adrenoceptor polymorphism and catecholamine effects on plasma-renin activity. J Am Coll Cardiol 2005; 46: 2111-5.
28. Merlet P, Valette H, Duboisrande JL, Moyse D, Duboc D, Dove P, Bourguignon MH, Benvenuti C, Duval AM, Agostini D, Loisance D, Castaigne A, Syrota A. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart-failure. J Nucl Med 1992; 33: 471-7.
29. Henneman MM, Bengel FM, Bax JJ. Will innervation imaging predict ventricular arrhythmias in ischaemic cardiomyopathy? Eur J Nucl Med Mol Imaging 2006; 33: 862-5.
30. Clark AL, Cleland JG. The control of adrenergic function in heart failure: therapeutic intervention. Heart Fail Rev 2000; 5: 101-14.
31. Molenaar P, Christ T, Ravens U, Kaumann A. Carvedilol blocks beta(2)- more than beta(1)-adrenoceptors in human heart. Cardiovasc Res 2006; 69: 128-39.
32. Lobmeyer MT, Gong Y, Terra SG, Beitelshees AL, Langaee TY, Pauly DF, Schofield RS, Hamilton KK, Herbert Patterson J, Adams KF, Jr, Hill JA, Aranda JM, Jr, Johnson JA. Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure. Pharmacogenet Genomics 2007; 17: 277-82.
33. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, Weber SA, Greene SM, Hodne D, Nelson B, Morrison J, Domanski MJ, Wagoner LE, Abraham WT, Anderson JL, Carlquist JF, Krause-Steinrauf HJ, Lazzeroni LC, Port JD, Lavori PW, Bristow MR. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci USA 2006; 103: 11288-93.
34. Tendera M. Epidemiology, treatment, and guidelines for the treatment of heart failure in Europe. Eur Heart J Suppl 2005; 7: J5-9.
35. Gislason GH, Rasmussen JN, Abildstrom SZ, Schramm TK, Hansen ML, Buch P, Sorensen R, Folke F, Gadsboll N, Rasmussen S, Kober L, Madsen M, Torp-Pedersen C. Persistent use of evidence-based pharmacotherapy in heart failure is associated with improved outcomes. Circulation 2007; 116: 737-44.